Statin clinical trial (REALITY) for prostate cancer: An over 15-year wait is finally over thanks to a dietary supplement

Urologic Clinics of North America

Volumn 38, Issue 3, 2011, Pages 325-331

  Moyad, Mark A ^a,b   Klotz, Laurence H ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b EISENHOWER MEDICAL CENTER   (United States)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Prostate cancer; REALITY trial; Red yeast rice; Statins

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MONACOLIN DERIVATIVE; MUSCLE ENZYME; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XUEZHIKANG;

ABSENCE OF SIDE EFFECTS; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CHINESE MEDICINE; DIET SUPPLEMENTATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FOOD COMPOSITION; FUNGAL STRAIN; HEART INFARCTION; HUMAN; LIFESTYLE MODIFICATION; MYALGIA; NONHUMAN; NUTRITIONAL VALUE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RICE; SIDE EFFECT; TREATMENT DURATION; YEAST;

BIOLOGICAL PRODUCTS; DIETARY SUPPLEMENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 79960626125     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.05.002     Document Type: Review

References (75)

1. van Adelsberg J., Gann P., Ko A.T., et al. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin 2007, 23:2063-2070.
2. Thompson I.M., Tangen C.M., Klein E.A., et al. Phase III prostate cancer prevention trials: are the costs justified?. J Clin Oncol 2005, 23:8161-8164.
3. Klein E.A., Thompson I.M., Lippman S.M., et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J Urol 2001, 166:1311-1315.
4. Moyad M.A. Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part I. Curr Opin Urol 2005, 15:1-6.
5. Moyad M.A. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I. Urol Oncol 2004, 22:466-471.
6. Moyad M.A. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II. Urol Oncol 2004, 22:472-477.
7. Moyad M.A., Merrick G.S. Statins and cholesterol lowering after a cancer diagnosis: why not?. Urol Oncol 2005, 23:49-55.
8. Moyad M.A., Merrick G.S., Butler W.M., et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005, 66:1150-1154.
9. Shannon J., Tewoderos S., Garzotto M., et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005, 162:318-325.
10. Cyrus-David M.S., Weinberg A., Thompson T., et al. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005, 173:1923-1925.
11. Zhuang L., Kim J., Adam R.M., et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005, 115:959-968.
12. Platz E.A., Leitzmann M.F., Visvanathan K., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006, 98:1819-1825.
13. Jacobs E.J., Rodriguez C., Bain E.B., et al. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:2213-2217.
14. Colli J.L., Amling C.L. Exploring causes for declining prostate cancer mortality rates in the United States. Urol Oncol 2008, 26:627-633.
15. Murtola T.J., Pennanen P., Syvala H., et al. Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate 2009, 69:1017-1023.
16. Loeb S., Kan D., Helfand B.T., et al. Is statin use associated with prostate cancer aggressiveness?. BJU Int 2010, 105:1222-1225.
17. Farwell W.R., D'Avolio L.W., Scranton R.E., et al. Statins and prostate cancer diagnosis and grade in a Veterans population. J Natl Cancer Inst 2011, 103:885-892.
18. Nijjar P.S., Burke F.M., Bloesch A., et al. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol 2010, 4:248-258.
19. Marinangeli C.P., Jones P.J., Kassis A.N., et al. Policosanols as nutraceuticals: fact or fiction. Crit Rev Food Sci Nutr 2010, 50:259-267.
20. Khoo Y.S., Aziz Z. Garlic supplementation and serum cholesterol: a meta-analysis. J Clin Pharm Ther 2009, 34:133-145.
21. Thompson Coon J.S., Ernst E. Herbs for serum cholesterol reduction: a systematic review. J Fam Pract 2003, 52:468-478.
22. Becker D.J., Gordon R.Y., Halbert S.C., et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150:830-839.
23. Venero C.V., Venero J.V., Wortham D.C., et al. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 2010, 105:664-666.
24. Halbert S.C., French B., Gordon R.Y., et al. Tolerability of red yeast rice (2400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010, 105:198-204.
25. Lu Z., Kou W., Du B., et al. Effects of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008, 101:1689-1693. Chinese Coronary Secondary Prevention Group.
26. Li C., Zhu Y., Wang Y., et al. Monascus purpureus fermented rice (red yeast rice): a natural food product that lowers blood cholesterol in animal models of hypercholesterolemia. Nutr Res 1998, 18:71-81. Red yeast rice. Med Lett Drugs Ther 2009;51:71-2.
27. Lin Y.-L., Wang T.-H., Lee M.-H., et al. Biologically active components and nutraceuticals in the Monascus-fermented rice: a review. Appl Microbiol Biotechnol 2008, 77:965-973.
28. Endo A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 1979, 32:852-854.
29. Landers P. Stalking cholesterol. How one scientist intrigued by molds found first statin. Feat of Japan's Dr. Endo led to heart-care revolution but brought him nothing. Nature as a drug laboratory. Wall Street Journal 2006, Dow Jones and Company, New York, p. A1, A8.
30. Becker D.J., Gordon R.Y., Morris P.B., et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc 2008, 83:758-764.
31. Liu J., Zhang J., Shi Y., et al. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 2006, 1:4.
32. China coronary secondary prevention study (CCSPS)-lipid regulating therapy with xuezhikang for secondary prevention of coronary heart disease. Chin J Cardiol (Chin) 2005, 33:109-115. China Coronary Secondary Prevention Study Group.
33. Ong H.T. The statin studies: from targeting hypercholesterolemia to targeting the high risk patient. QJM 2005, 98:599-614.
34. Zhao S.P., Lu Z.L., Du B.M., et al. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from Chian coronary secondary prevention study (CCSPS). J Cardiovasc Pharmacol 2007, 49:81-84. China Coronary Secondary Prevention Study.
35. Ye P., Lu Z.L., Du B.M., et al. Effects of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from China coronary secondary prevention study. J Am Geriatr Soc 2007, 55:1015-1022. CCSPS Investigators.
36. Li J.J., Lu Z.L., Kou W.R., et al. Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS). Clin Exp Hypertens 2010, 32(8):491-498. Chinese Coronary Secondary Prevention Study (CCSPS) Group.
37. Huang C.F., Li T.C., Lin C.C., et al. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil 2007, 14:438-440.
38. Lin C.C., Li T.C., Lai M.M. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 2005, 153:679-686.
39. Heber D., Yip I., Ashley J.M., et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999, 69:231-236.
40. Bogsrud M.P., Ose L., Langslet G., et al. HypoCol (red yeast rice) lowers plasma cholesterol-a randomized placebo controlled study. Scand Cardiovasc J 2010, 44:197-200.
41. Guardamagna O., Abello F., Baracco V., et al. The treatment of hypercholesterolemic children: Efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis 2011, 21:424-429.
42. Hong M.Y., Seeram N.P., Zhang Y., et al. Chinese red yeast rice versus lovastatin effects on prostate cancer cells with and without androgen receptor overexpression. J Med Food 2008, 11:657-666.
43. Hong M.Y., Henning S., Moro A., et al. Chinese red yeast rice inhibition of prostate tumor growth in SCID mice. Cancer Prev Res (Phila) 2011, 4:608-615.
44. Hong M.Y., Seeram N.P., Zhang Y., et al. Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. J Nutr Biochem 2008, 19:448-458.
45. Ma K.Y., Zhang Z.S., Zhao S.X., et al. Red yeast increases excretion of bile acids in hamsters. Biomed Environ Sci 2009, 22:269-277.
46. Li J.J., Hu S.S., Fang C.H., et al. Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clin Chim Acta 2005, 352:217-224.
47. Zhao S.P., Liu L., Cheng Y.C., et al. Xuezhikang, an extract of cholestin, protects endothelial function through anti-inflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004, 110:915-920.
48. Liu L., Zhao S.P., Cheng Y.C., et al. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem 2003, 49:1347-1352.
49. Eisberger B., Lankston L., McMillan D.C., et al. Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer Prostatic Dis 2011, 14:122-128.
50. Lehrer S., Diamond E.J., Mamkine B., et al. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005, 95:961-962.
51. Solomon K.R., Pelton K., Boucher K., et al. Ezetimibe is an inhibitor if tumor angiogenesis. Am J Pathol 2009, 174:1017-1026.
52. Murtola T.J., Visakorpi T., Lahtela J., et al. Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol 2008, 5:376-387.
53. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 2006, 7:355-362.
54. Gotto A.M., Whitney E., Stein E.A., et al. Relation between baseline and on treatment lipid parameters and first major acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000, 101:477-484.
55. Nakamura H. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atheroscler Suppl 2007, 8:13-17. MEGA Study Group.
56. Gordon R.Y., Cooperman T., Obermeyer W., et al. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware. Arch Intern Med 2010, 170:1722-1727.
57. Harding A. Contamination common in red yeast rice products 2008, Thompson Reuters, New York, Available at:, Accessed April 25, 2011. http://www.reuters.com/article/healthNews/idUSCOL97022820080709.
58. Klimek M., Wang S., Ogunkanmi A. Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P T 2009, 34:313-327.
59. Heber D., Lembertas A., Lu Q.Y., et al. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001, 7:133-139.
60. Abd T.T., Jacobson T.A. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011, 10:373-387.
61. Eckel R.H. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 2010, 95:2015-2022.
62. Kelly R.B. Diet and exercise in the management of hyperlipidemia. Am Fam Physician 2010, 81:1097-1102.
63. Lin J.S. An alternative treatment of hyperlipidemia with red yeast rice: a case report. J Med Case Reports 2010, 4:4.
64. Roselle H., Ekatan A., Tzeng J., et al. Symptomatic hepatitis associated with the use of herbal red yeast rice [letter]. Ann Intern Med 2008, 149:516-517.
65. Grieco A., Miele L., Pompili M., et al. Acute hepatitis caused by a natural lipid-lowering product: when " alternative" medicine is no " alternative" at all. J Hepatol 2009, 50:1273-1277.
66. Polsani V.R., Jones P.H., Ballantyne C.M., et al. A case report of myopathy from consumption of red yeast rice. J Clin Lipidol 2008, 2:60-62.
67. Lapi F., Gallo E., Bernasconi S., et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products [letter]. Br J Clin Pharmacol 2008, 66:572-574.
68. Mueller P.S. Symptomatic myopathy due to red yeast rice [letter]. Ann Intern Med 2006, 145:474-475.
69. Smith D.J., Olive K.E. Chinese red rice-induced myopathy. South Med J 2003, 96:1265-1267.
70. Vercelli L., Mongini T., Olivero N., et al. Chinese red rice depletes muscle coenzyme Q10 and maintains muscle damage after discontinuation of statin treatment [letter]. J Am Geriatr Soc 2006, 54:718-720.
71. Cartin-Ceba R., Lu L.B., Kolpakchi A. A " natural" threat. Am J Med 2007, 120:e3-e4. [letter].
72. Prasad G.V., Wong T., Meliton G., et al. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002, 74:1200-1201.
73. Garnett W.R. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995, 52:1639-1645.
74. Schacter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005, 19:117-125.
75. Moghadasian M.H. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 1999, 65:1329-1337.